參考文獻(xiàn)/References:
[1] Smith M A.Outcomes for children and adolescents with cancer: challenges for the twenty-first century[J].J Clin Oncol, 2010, 28(15):2625-2634.
[2] McKeown M R, Bradner J E.Therapeutic strategies to inhibit MYC[J].Cold Spring Harb Perspect Med, 2014, 4(10):12-18.
[3] 翁克貴,蔣勇,王穎.干擾 c-myc 基因表達(dá)增強(qiáng)人胰腺癌細(xì)胞對(duì)吉西他濱和卡鉑的敏感性[J].腫瘤藥學(xué), 2017, 7(3): 273-277.
[4] 趙迎春，馮娥，田云云.骨肉瘤的免疫檢查點(diǎn)及其抑制劑應(yīng)用的研究進(jìn)展[J].廣西醫(yī)學(xué), 2020, 42(7): 891-894.
[5] 林澤鑫,林欣.免疫檢測(cè)點(diǎn)抑制劑及其生物標(biāo)志物在晚期實(shí)體腫瘤中的研究進(jìn)展[J].中國實(shí)用醫(yī)藥, 2019, 14(2): 190-193.
[6] 周靈，謝琳，廖冶丹，等.骨肉瘤轉(zhuǎn)移機(jī)制研究進(jìn)展[J].中華轉(zhuǎn)移性腫瘤雜志，2019，2(3):55-59.
[7] Wang O, Yang F, Liu Y, et al.C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer[J].Am J Transl Res, 2017, 9(2): 533-545.
[8] 施錦濤，張凱，張芮浩，等.PD-1/PD-L1軸與骨肉瘤治療研究進(jìn)展[J].解放軍醫(yī)學(xué)雜志, 2021, 46(1): 89-94.
[9] Shimizu T, Fuchimoto Y, Fukuda K, et al.The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma[J].J Pediatr Surg, 2017, 52(12): 2047-2050.
[10] Casey S C，Tong L，Li Y，et al.MYC regulates the antitumor immune response through CD47 and PD-L1[J].Science,2016,352(6282):227-231.
[11] 黃杰中,陳敬恒.c-myc蛋白及凋亡抑制、促進(jìn)因子在骨肉瘤中的檢測(cè)價(jià)值探究[J].中國醫(yī)學(xué)創(chuàng)新, 2021, 18(9):138-142.
[12] Zheng B,Ren T,Huang Y,et al.PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse[J].J HematolOncol, 2018, 11(1): 16.